Guardian Asset Advisors LLC Sells 43 Shares of Veeva Systems Inc. $VEEV

Guardian Asset Advisors LLC reduced its holdings in Veeva Systems Inc. (NYSE:VEEV) by 4.7% in the 2nd quarter, Holdings Channel reports. The fund owned 881 shares of the technology company’s stock after selling 43 shares during the quarter. Guardian Asset Advisors LLC’s holdings in Veeva Systems were worth $254,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. TFB Advisors LLC increased its holdings in shares of Veeva Systems by 1.2% in the first quarter. TFB Advisors LLC now owns 3,586 shares of the technology company’s stock worth $831,000 after acquiring an additional 44 shares in the last quarter. Triangle Securities Wealth Management boosted its position in shares of Veeva Systems by 0.8% during the second quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock worth $1,665,000 after buying an additional 45 shares during the period. Marks Group Wealth Management Inc boosted its position in shares of Veeva Systems by 3.3% during the first quarter. Marks Group Wealth Management Inc now owns 1,427 shares of the technology company’s stock worth $331,000 after buying an additional 46 shares during the period. Harbour Investments Inc. boosted its position in shares of Veeva Systems by 7.6% during the first quarter. Harbour Investments Inc. now owns 789 shares of the technology company’s stock worth $183,000 after buying an additional 56 shares during the period. Finally, Parallel Advisors LLC boosted its position in shares of Veeva Systems by 4.7% during the second quarter. Parallel Advisors LLC now owns 1,236 shares of the technology company’s stock worth $356,000 after buying an additional 56 shares during the period. 88.20% of the stock is currently owned by institutional investors.

Insider Transactions at Veeva Systems

In other news, SVP Jonathan Faddis sold 14,595 shares of the stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $300.00, for a total transaction of $4,378,500.00. Following the transaction, the senior vice president owned 8,588 shares in the company, valued at approximately $2,576,400. This trade represents a 62.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total value of $1,839,720.00. Following the transaction, the insider owned 25,325 shares in the company, valued at approximately $7,765,151.50. This trade represents a 19.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,665 shares of company stock worth $7,438,000. Company insiders own 10.30% of the company’s stock.

Veeva Systems Stock Up 0.6%

VEEV opened at $291.66 on Friday. Veeva Systems Inc. has a 12-month low of $201.54 and a 12-month high of $310.50. The stock has a market cap of $47.81 billion, a price-to-earnings ratio of 59.89, a PEG ratio of 2.24 and a beta of 0.98. The business has a 50 day moving average of $284.44 and a 200-day moving average of $268.67.

Veeva Systems (NYSE:VEEV) last announced its earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). The firm had revenue of $789.08 million for the quarter, compared to the consensus estimate of $768.49 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.Veeva Systems’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter last year, the business posted $1.62 EPS. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. As a group, analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on VEEV. Morgan Stanley upped their price objective on Veeva Systems from $210.00 to $222.00 and gave the stock an “underweight” rating in a research report on Thursday, August 28th. Wells Fargo & Company upped their price objective on Veeva Systems from $300.00 to $326.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 26th. KeyCorp upped their price objective on Veeva Systems from $285.00 to $325.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. TD Cowen raised Veeva Systems from a “hold” rating to a “buy” rating and increased their price target for the company from $297.00 to $380.00 in a research report on Tuesday, October 7th. Finally, Stifel Nicolaus increased their price target on Veeva Systems from $295.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Seventeen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $307.58.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.